CHIMERIC ANTIGEN RECEPTORS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III

The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cell...

Full description

Saved in:
Bibliographic Details
Main Authors WONG, Oi Kwan, CHOU, Joyce Ching, SASU, Barbra Johnson, DUSSEAUX, Mathilde Brunnhilde, SMITH, Julianne
Format Patent
LanguageEnglish
Published 16.05.2019
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
Bibliography:Application Number: US201916255348